Introduction {#s1}
============

Breast cancer (BCa) is the most frequently diagnosed malignancy and the leading cause of cancer-related mortality among women worldwide ([@B1]). There were 2,088,849 new BCa cases and 358,989 deaths from BCa in 2018, accounting for 24.2% of all cancer cases and 15.0% of total deaths among global malignancies in women ([@B2]). BCa can be divided into four major subtypes according to the expression status of the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2), namely, luminal A, luminal B, HER2+, and triple-negative BCa ([@B3]). However, emerging data indicate an increase in the incidence of resistance to endocrine therapy, especially in luminal B BCa ([@B4]). Arpino et al. reported that the decreased sensitivity of luminal B BCa to endocrine therapy might be triggered by the crosstalk between ER and HER2 ([@B5]). Therefore, novel strategies to inhibit the activity of HER2 may increase the therapeutic efficacy of endocrine therapy in hormone receptor-positive BCa patients.

Toll-like receptors (TLRs) are a family of innate immune receptors that can recognize ligands derived from viruses, bacteria, parasites, and fungi ([@B6]). TLRs play important roles in the regulation of inflammatory responses aimed at eliminating pathogen infection and cancer debris ([@B7]). In addition, they play regulatory roles in cell proliferation and apoptosis in both normal and tumor cells ([@B8], [@B9]). Increasing evidence supports the double-edged sword effect of TLRs in cancer cells, because uncontrolled TLR signaling leads to a microenvironment that promotes tumor growth ([@B10], [@B11]). The TLR family is divided into two major subtypes according to cellular localization. TLR 1, 2, 5, 6, and 10 are extracellular TLRs, whereas TLR3, 7, 8, and 9 are localized in intracellular organelles ([@B12]). TLR2 and TLR4 are two major TLRs that have been widely investigated for their involvement in inflammatory responses and cancers ([@B13]). The expression and clinical significance of TLR4 have been reported in patients with BCa ([@B14]). TLR2 polymorphisms are associated with BCa risk ([@B10]), and TLR2 is involved in immunomodulation in BCa ([@B15]). TLR2 is upregulated in most tumors and closely associated with tumor metastasis, playing an important role as a proto-oncogene ([@B16], [@B17]). In colorectal cancer, TLR2 promotes tumor cell proliferation, migration, and invasion by activating the PI3K/AKT signaling pathway ([@B18]). However, the clinical significance of TLR2 in BCa remains unclear. Lu et al. showed that TLR2 agonists enhance the efficacy of HER2-targeted monoclonal antibody therapy ([@B19]). Considering the important role of HER2 in endocrine therapy resistance in BCa, we investigated the potential role of TLR2 in regulating the sensitivity to endocrine therapy in BCa.

In the current study, changes in the expression of TLR2 in BCa patients and patients with endocrine therapy resistance were investigated, and the clinical significance of TLR2 as a prognostic factor for BCa was evaluated. In addition, we assessed the value of TLR2 for predicting endocrine therapy resistance in patients with luminal BCa.

Methods and Materials {#s2}
=====================

Patients and Tissue Samples
---------------------------

The study enrolled 150 patients who were histopathologically diagnosed with BCa in Shaanxi Provincial Cancer Hospital affiliated to the Medical School between 2011 and 2013. None of the patients received anti-tumor therapy before sampling. Of the 150 BCa patients, 68 underwent surgical resection and 82 received endocrine therapy. BCa tissues and adjacent normal tissues were collected from the patients and frozen in liquid nitrogen for further use. The experimental procedures were approved by the Ethics Committee of Shaanxi Provincial Cancer Hospital, and written informed consent was obtained from each participant.

Clinical Data Collection
------------------------

The demographic and clinicopathological characteristics of the patients were recorded, including age, tumor size, ER, PR, and HER2 status; tumor subtypes; and TNM stage. ER, PR, and HER2 \[FISH (Fluorescence *in situ* hybridization) was used to characterize HER2 expression in IHC (Immunohistochemistry) 2+ cases\] status was examined by immunohistochemistry, and BCa subtypes were categorized following the St. Gallen Expert Consensus as follows: luminal A (ER+ and/or PR+, HER2--, Ki-67 \<14%), luminal B (ER+ and/or PR+, HER2--, Ki-67 ≥14%; ER+ and/or PR+, HER2+), HER2+ (ER--, PR--, HER2+), and triple-negative (ER--, PR--, HER2--) ([@B20]). The TNM stage of BCa patients was determined according to the criteria published by the American Joint Committee on Cancer Classification ([@B21]). Overall survival (OS) was defined as the percentage of cases who had been alive after a number of months. The duration is from the beginning of filtering to death. In addition, survival information and the rates of endocrine therapy resistance \[primary endocrine resistance was defined as recurrence within 2 years prior to adjuvant endocrine therapy or progression within 6 months prior to first-line endocrine therapy for metastatic BCa ([@B22])\] of the patients were collected from a 5-year follow-up survey for the subsequent survival analysis.

RNA Extraction
--------------

Total RNA was extracted from tissues using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The concentration and purity of RNA were evaluated using a NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Single stranded cDNA was synthesized from 2 μg RNA using a reverse transcription reagent kit (Invitrogen) according to the manufacturer\'s instructions.

Quantitative Real-Time PCR (qRT-PCR)
------------------------------------

The mRNA expression of TLR2 in tissue samples was assessed by qRT-PCR using a SYBR Green PCR kit (TaKaRa, Dalian, China) on a 7,500 Real-Time PCR System (Applied Biosystems, USA). GAPDH was used as the internal control gene, and the relative expression of TLR2 was calculated using the 2^−ΔΔCt^ method.

Statistical Analysis
--------------------

Data were expressed as the mean ± SD and analyzed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 software (GraphPad Software, Inc., USA). A K-S test was used to test the normality of TLR2. Differences between groups were analyzed using the Student\'s *t*-test, one-way ANOVA, or the Chi-square test. Kaplan-Meier (KM) survival curves were generated to determine the prognostic value of TLR2. A receiver operating characteristic curve (ROC) was plotted to assess the value of TLR2 for predicting the occurrence of endocrine resistance. A proportional hazards model (Cox) was used for multi-factor prognostic analysis. A *P* \< 0.05 was considered to indicate statistical significance.

Results {#s3}
=======

Expression of TLR2 in Patients With BCa
---------------------------------------

The results of qRT-PCR indicated that TLR2 mRNA expression was significantly higher in BCa tissues than in normal tissues (*P* \< 0.001, [Figure 1A](#F1){ref-type="fig"}). In the 5-year follow-up, there were 24 patients with resistance to endocrine therapy, accounting for 29.3% of the 82 BCa patients who received endocrine therapy. TLR2 mRNA expression was significantly higher in the resistant group than in the sensitive group (*P* \< 0.001, [Figure 1B](#F1){ref-type="fig"}).

![Expression of TLR2 in BCa patients. **(A)** The mRNA expression of TLR2 in BCa tissues was increased compared with the normal controls. **(B)** The relative TLR2 expression was elevated in the BCa patients with resistance of endocrine therapy. \*\*\**P* \< 0.001.](fonc-10-00547-g0001){#F1}

Association of TLR2 With Clinicopathological Data of BCa Patients
-----------------------------------------------------------------

Considering that TLR2 is dysregulated in BCa tissues, this study analyzed the relationship between TLR2 expression and the clinicopathological features of BCa patients. The distribution of TLR2 was a normal distribution (*p* = 0.087). The patients were therefore divided into TLR2- low and -high expression groups according to mean TLR2 expression values. As shown in [Table 1](#T1){ref-type="table"}, the mRNA expression levels of TLR2 were associated with tumor size, subtypes, and TNM stage (all *P* \< 0.05). TLR2 expression was associated with HER2 status (*P* = 0.025). There was no statistically significant association between TLR2 and patient age, ER status, and PR status (all *P* \> 0.05).

###### 

Relationship between TLR2 expression and clinicopathological features of BCa patients.

  **Features**      **Total No**.   **TLR2 expression**   ***P*-values**   
  ----------------- --------------- --------------------- ---------------- ----------------------------------------
  Age (years)                                                              0.574
  ≤50               59              30                    29               
  \>50              91              42                    49               
  Tumor size (cm)                                                          0.036[^\*^](#TN1){ref-type="table-fn"}
  ≤2                70              40                    30               
  \>2               80              32                    48               
  ER status                                                                0.392
  Negative          51              22                    29               
  Positive          99              50                    49               
  PR status                                                                0.647
  Negative          57              26                    31               
  Positive          93              46                    47               
  HER2 status                                                              0.025[^\*^](#TN1){ref-type="table-fn"}
  Negative          108             58                    50               
  Positive          42              14                    28               
  Subtypes                                                                 0.001[^\*^](#TN1){ref-type="table-fn"}
  Luminal A         68              44                    24               
  Luminal B         42              12                    30               
  HER2+             18              6                     12               
  Triple-negative   22              10                    12               
  TNM stage                                                                0.030[^\*^](#TN1){ref-type="table-fn"}
  I--II             95              52                    43               
  III--IV           55              20                    35               

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2;

*P \< 0.05*.

Prognostic Value of TLR2 in Patients With BCa
---------------------------------------------

The value of TLR2 for predicting the prognosis of BCa was evaluated in the present study. In the entire BCa patient cohort, KM survival curves showed that high TLR2 expression was associated with poor overall survival compared with that of patients with low TLR2 levels (log-rank *P* = 0.004, [Figure 2A](#F2){ref-type="fig"}). In BCa patients who underwent surgery, high TLR2 mRNA levels were also associated with a shorter survival time (log-rank *P* = 0.037, [Figure 2B](#F2){ref-type="fig"}), and a similar pattern was observed in patients receiving endocrine therapy, in which high TLR2 mRNA expression was associated with poor overall survival compared with that of patients with low TLR2 expression (log-rank *P* = 0.014, [Figure 2C](#F2){ref-type="fig"}) While in the entire BCa patient cohort, KM survival curves showed that high TLR2 expression was also associated with poor disease free survival compared with that of patients with low TLR2 levels (log-rank *P* = 0.001, [Figure 2D](#F2){ref-type="fig"}). Moreover, in a Cox model adjusted for method of therapy, TNM stage, level of Her2 and subtypes, patients with high level TLR2 had an elevated hazard ratio, and it was statistically significant (HR 1.87, 95% CI: 1.02--3.40, *p* = 0.042; [Table 2](#T2){ref-type="table"}). So, the TLR2 level was an independent role to be associated with BCa prognostic.

![Kaplan-Meier (KM) overall survival curves constructed with the expression of TLR2. **(A)** The KM curves for the total study population. **(B)** The KM curves for patients received surgery. **(C)** The KM curves for patients underwent endocrine therapy. **(D)** The KM disease free survival curves constructed with the expression of TLR2.](fonc-10-00547-g0002){#F2}

###### 

Results from a multivariate Cox model for testing the impact of TRL2 on 5-year survival; Method of therapy, TNM stage, level of Her2 and subtypes are adjustment factors.

  **Contributing factors**   **N**   **Univariate HR**   **HR**   **95% CI**      ***p*-value**
  -------------------------- ------- ------------------- -------- --------------- ---------------
  High level of Her2         42      3.103               6.412    1.456--28.236   0.014
  High level of TLR2         78      2.3                 1.865    1.022--3.406    0.042
  Surgery therapy            34      1.809               1.574    0.899--2.757    0.112
  TNM stage III--IV          55      3.181               2.168    1.084--4.338    0.029
  Luminal A                  68                                                   0.039
  Luminal B                  42      1.245               2.903    1.255--6.713    0.013
  HER2+                      18      1.31                4.95     1.098--22.222   0.037
  Triple-negative            22      4.184               5.495    1.009--30.303   0.049

*95% CI, 95% confidence interval; HR, harzard ratio*.

The Value of TLR2 for Predicting Endocrine Therapy Resistance
-------------------------------------------------------------

Given the deregulated expression pattern of TLR2 and its association with poor prognosis in patients receiving endocrine therapy, this study used a ROC curve to determine the value of TLR2 for predicting the development of resistance to endocrine therapy which was the cut-off value. As shown [Figure 3](#F3){ref-type="fig"}, the area under the curve (AUC) was 0.910, indicating a high accuracy of TLR2 for distinguishing resistant from sensitive BCa cases. At an optimal cutoff value of 1.228, the sensitivity was 79.2% and the specificity was 86.2%.

![A ROC curve to evaluate the predictive value of TLR2 for the occurrence of endocrine resistance. AUC, area under the curve.](fonc-10-00547-g0003){#F3}

Value of TLR2 for Predicting Endocrine Therapy Resistance in Different Subtypes of BCa
--------------------------------------------------------------------------------------

The present results suggest an association between TLR2 and HER2 and demonstrate the value of TLR2 for predicting endocrine therapy resistance. Considering HER2 status among BCa subtypes, we further investigated the clinical role of TLR2 in predicting endocrine therapy resistance by dividing BCa patients into luminal A (*n* = 45), HER2-negative luminal B (*n* = 21), and HER-positive luminal B cases (*n* = 16). The resistance rates among BCa patients are listed in [Table 3](#T3){ref-type="table"}. HER-positive luminal B patients had higher rates of resistance than luminal A and HER2-negative luminal B patients (*P* \< 0.01), which was consistent with previous studies reporting the inhibitory effects of HER2 on endocrine therapy sensitivity ([@B23]). As shown in [Figure 4A](#F4){ref-type="fig"}, TLR2 mRNA expression was significantly higher in HER2-positive luminal B cases than in luminal A and HER2-negatie luminal B cases (*P* \< 0.05). Furthermore, ROC curves based on TLR2 expression indicated that TLR2 could predict the resistance to endocrine therapy in the three subtypes; the AUC for the HER2-positive luminal B cases was relatively high among the three subtypes (AUC = 0.983, [Figures 4B--D](#F4){ref-type="fig"}).

###### 

Endocrine therapy resistance in different BCa subtypes.

  **Indicators**        **Luminal A**   **HER2-negative luminal B**   **HER2-positive luminal B**   ***P~**1**~***   ***P~**2**~***   ***P~**3**~***
  --------------------- --------------- ----------------------------- ----------------------------- ---------------- ---------------- ----------------
  Total number          45              21                            16                            0.724            0.002            0.018
  Resistance number     9               5                             10                                                              
  Resistance rate (%)   20.00%          23.80%                        62.50%                                                          

*HER2, human epidermal growth factor receptor 2; P1, Luminal A vs. HER2-negative luminal B; P2, Luminal A vs. HER2-positive luminal B; P3, HER2-negative luminal B vs. HER2-positive luminal B*.

![Predictive value of TLR2 for endocrine resistance in different subtypes of BCa patients. **(A)** Expression of TLR2 in different subtypes of BCa patients. **(B)** A ROC curve to evaluate the predictive value of TLR2 for endocrine resistance in luminal A subtype. **(C)** A ROC curve to evaluate the predictive value of TLR2 for endocrine resistance in HER-negative luminal B subtype. **(D)** A ROC curve to evaluate the predictive value of TLR2 for endocrine resistance in HER-positive luminal B subtype. AUC, area under the curve. \**p* \< 0.05 vs Luminal A and HER2-negative luminal B.](fonc-10-00547-g0004){#F4}

Discussion {#s4}
==========

BCa is the most common malignancy among women worldwide. This study aimed to provide a novel biomarker for predicting the prognosis of BCa and the resistance to endocrine therapy. The results of the present study indicated that TLR2 mRNA expression was higher in BCa tissues than in normal tissues and associated with tumor size, HER2 status, tumor subtype, and TNM stage. BCa patients with high TLR2 expression had a shorter overall survival than those with low TLR2 expression. In addition, TLR2 was significantly upregulated in patients showing resistance to endocrine therapy, supporting its value as an indicator to predict the development of endocrine resistance in BCa patients. TLR2 expression was higher in the HER2-positive luminal B BCa subtype than in the other hormone receptor-positive BCa cases, and its predictive value for the resistance to endocrine therapy was relatively high in the HER2-positive luminal B subtype.

The incidence and mortality rates of BCa are increasing worldwide ([@B2]). Despite advances in BCa treatment methods, the prognosis of patients with this malignancy remains unsatisfactory. Various molecules involved in the initiation and progression of BCa show aberrant expression patterns ([@B24]). Qiu et al. found that Cullin 7 is upregulated in BCa tissues and serves as a candidate prognostic biomarker and oncogene ([@B25]). Zhang et al. investigated the expression and clinical significance of CD81 in patients with BCa, and provided evidence for CD81 upregulation as a prognostic biomarker and an oncogene that promotes BCa cell migration and proliferation ([@B26]). Dai et al. showed that CST1 is upregulated in BCa tissues, and increased CST1 expression predicts a poor prognosis and facilitates tumor progression ([@B27]). These studies prompted us to identify novel molecules showing abnormal expression that may serve as biomarkers to improve the prognosis and treatment of BCa.

TLRs play pivotal roles in the activation of immune responses. Studies indicate that TLRs are critical mediators of chronic inflammation in the tumor microenvironment that promote the survival of tumor cells ([@B28]). TLR2 is one the most extensively investigated members of the TLR family. West et al. reported that elevated TLR2 level is associated with key genes involved in gastric cancer prognosis and identified TLR2 as a potential therapeutic target in this malignancy ([@B29]). Another study in gastric cancer provided additional evidence supporting the role of TLR2 in the inflammatory microenvironment and in promoting tumor progression ([@B30]). In glioma, TLR2 facilitates tumor cell immune evasion ([@B31]). TLR2 polymorphisms are correlated with the risk of BCa ([@B10]) and contribute to BCa cell invasion ([@B32]). However, the clinical significance of TLR2 in BCa remains elusive. Analysis of the survival of BCa patients indicated that patients with high TLR2 expression had a poorer prognosis than those with low TLR2 expression. These results indicate that TLR2 upregulation in BCa patients might predict a poor prognosis.

The development of resistance to endocrine therapy, especially in HER2-positive luminal B BCa cases, has attracted increasing attention ([@B33]). Dormant/quiescent/slow-cycle cancer stem cells (CSCs) are key factors associated with tumor heterogeneity and are responsible for tumor resistance, migration, and metastatic dormancy, which is the ability of CSCs to survive in target organs and lead to metastasis within 20 years of diagnosis. CSCs interact with the tumor microenvironment to self-renew, resist radiation and chemotherapy, and produce distant metastases ([@B34], [@B35]). BHLHE41 (basic helix-loop-helix family, member e41) and NR2F1 (nuclear receptor subfamily 2 group F member 1) promote the growth of ER positive MCF7 cells *in vivo*. Analysis of patient data suggests that ER-positive diffuse tumor cells with dormancy characteristics are more likely to undergo prolonged dormancy before resuming metastatic growth. ([@B36], [@B37]).

The crosstalk between ER and HER2 may contribute to the resistance to endocrine therapy, as indicated by the enhanced HER2 activity in BCa cases treated with ER inhibitors ([@B5]). Identifying novel strategies to improve the therapeutic efficacy of endocrine therapy is critical. Keegan et al. reported that inhibiting PI3K activity may be a strategy to overcome endocrine resistance in BCa ([@B38]). Charmsaz et al. demonstrated that the upregulation of S100 β in BCa patients is involved in endocrine resistance and serves as a promising biomarker for the response to endocrine therapy ([@B39]). Lee et al. provided evidence supporting the role of MTA1 (metastasis associated 1) as a key regulator of endocrine therapy resistance by modulating autophagy ([@B40]). In this study, TLR2 was upregulated in BCa patients with endocrine resistance, and its expression was effective for distinguishing resistant from sensitive cases, indicating the predictive potential of TLR2 for endocrine therapy resistance. In addition, we found an association between TLR2 and HER2. These data combined with the important role of HER2 in endocrine resistance led us to speculate that TLR2 might be involved in the development of endocrine resistance through the HER2 signaling pathway. However, this hypothesis needs to be analyzed and confirmed in further studies.

Taken together, the present data indicate that elevated TLR2 expression is a candidate prognostic biomarker in BCa and may predict the development of endocrine resistance. We identified a relationship between TLR2 and HER2, and showed that the value of TLR2 for predicting the response to endocrine therapy was particularly high in the HER-positive luminal B subtype, indicating that TLR2 may be involved in the regulation of endocrine therapy sensitivity through the HER signaling pathway.

A greater number of samples and validation at different levels may be necessary to verify our results, as this study was limited by a small sample size. In addition, TLR2-related pathways need to be examined in different tissues and cells, and the possible relationship of TLR2 with dormancy in BCa should be investigated in the future.
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